Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306173665> ?p ?o ?g. }
- W4306173665 endingPage "163" @default.
- W4306173665 startingPage "154" @default.
- W4306173665 abstract "PurposeThe purpose of this article is to evaluate the safety of two regorafenib dose-escalation approaches in refractory metastatic colorectal cancer (mCRC) patients.Patients and methodsPatients with mCRC and progression during or within 3 months following their last standard chemotherapy regimen were randomised to receive the approved dose of regorafenib of 160 mg QD (arm A) or 120 mg QD (arm B) administered as 3 weeks of treatment followed by 1 week off, or 160 mg QD 1 week on/1 week off (arm C). The primary end-point was the percentage of patients with G3/G4 treatment-related adverse events (AEs) in each arm.ResultsThere were 299 patients randomly assigned to arm A (n = 101), arm B (n = 99), or arm C (n = 99); 297 initiated treatments (arm A n = 100, arm B n = 98, arm C n = 99: population for safety analyses). G3/4 treatment-related AEs occurred in 60%, 55%, and 54% of patients in arms A, B, and C, respectively. The most common G3/4 AEs were hypertension (19, 12, and 20 patients), fatigue (20, 14, and 15 patients), hypokalemia (11, 7, and 10 patients), and hand–foot skin reaction (8, 7, and 3 patients). Median overall survival was 7.4 (IQR 4.0–13.7) months in arm A, 8.6 (IQR 3.8–13.4) in arm B, and 7.1 (IQR 4.4–12.4) in arm C.ConclusionsThe alternative regorafenib dosing schedules were feasible and safe in patients with mCRC who had been previously treated with standard therapy. There was a higher numerical improvement on the most clinically relevant AEs in the intermittent dosing arm, particularly during the relevant first two cycles.Clinicaltrials.gov identifierNCT02835924." @default.
- W4306173665 created "2022-10-14" @default.
- W4306173665 creator A5003707413 @default.
- W4306173665 creator A5007751144 @default.
- W4306173665 creator A5012034272 @default.
- W4306173665 creator A5014199274 @default.
- W4306173665 creator A5015190461 @default.
- W4306173665 creator A5015509025 @default.
- W4306173665 creator A5016557012 @default.
- W4306173665 creator A5017132355 @default.
- W4306173665 creator A5020788874 @default.
- W4306173665 creator A5028160510 @default.
- W4306173665 creator A5029973306 @default.
- W4306173665 creator A5030215661 @default.
- W4306173665 creator A5032522211 @default.
- W4306173665 creator A5032532248 @default.
- W4306173665 creator A5036625532 @default.
- W4306173665 creator A5041203253 @default.
- W4306173665 creator A5043177546 @default.
- W4306173665 creator A5048085062 @default.
- W4306173665 creator A5048352947 @default.
- W4306173665 creator A5053880366 @default.
- W4306173665 creator A5054413273 @default.
- W4306173665 creator A5054498659 @default.
- W4306173665 creator A5058504422 @default.
- W4306173665 creator A5059645677 @default.
- W4306173665 creator A5060569859 @default.
- W4306173665 creator A5068189051 @default.
- W4306173665 creator A5072578892 @default.
- W4306173665 creator A5073742272 @default.
- W4306173665 creator A5073894797 @default.
- W4306173665 creator A5077892396 @default.
- W4306173665 creator A5080788977 @default.
- W4306173665 creator A5081985776 @default.
- W4306173665 creator A5085058149 @default.
- W4306173665 creator A5085339887 @default.
- W4306173665 creator A5089849734 @default.
- W4306173665 creator A5090464803 @default.
- W4306173665 date "2022-12-01" @default.
- W4306173665 modified "2023-10-16" @default.
- W4306173665 title "A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial)" @default.
- W4306173665 cites W2009035857 @default.
- W4306173665 cites W2073864895 @default.
- W4306173665 cites W2111851685 @default.
- W4306173665 cites W2112727687 @default.
- W4306173665 cites W2125763124 @default.
- W4306173665 cites W2128403792 @default.
- W4306173665 cites W2133399075 @default.
- W4306173665 cites W2147834058 @default.
- W4306173665 cites W2151507583 @default.
- W4306173665 cites W2165094466 @default.
- W4306173665 cites W2166525855 @default.
- W4306173665 cites W2260992463 @default.
- W4306173665 cites W2470575266 @default.
- W4306173665 cites W2590275012 @default.
- W4306173665 cites W2891319811 @default.
- W4306173665 cites W2913372216 @default.
- W4306173665 cites W2954373381 @default.
- W4306173665 doi "https://doi.org/10.1016/j.ejca.2022.09.037" @default.
- W4306173665 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36335783" @default.
- W4306173665 hasPublicationYear "2022" @default.
- W4306173665 type Work @default.
- W4306173665 citedByCount "1" @default.
- W4306173665 countsByYear W43061736652023 @default.
- W4306173665 crossrefType "journal-article" @default.
- W4306173665 hasAuthorship W4306173665A5003707413 @default.
- W4306173665 hasAuthorship W4306173665A5007751144 @default.
- W4306173665 hasAuthorship W4306173665A5012034272 @default.
- W4306173665 hasAuthorship W4306173665A5014199274 @default.
- W4306173665 hasAuthorship W4306173665A5015190461 @default.
- W4306173665 hasAuthorship W4306173665A5015509025 @default.
- W4306173665 hasAuthorship W4306173665A5016557012 @default.
- W4306173665 hasAuthorship W4306173665A5017132355 @default.
- W4306173665 hasAuthorship W4306173665A5020788874 @default.
- W4306173665 hasAuthorship W4306173665A5028160510 @default.
- W4306173665 hasAuthorship W4306173665A5029973306 @default.
- W4306173665 hasAuthorship W4306173665A5030215661 @default.
- W4306173665 hasAuthorship W4306173665A5032522211 @default.
- W4306173665 hasAuthorship W4306173665A5032532248 @default.
- W4306173665 hasAuthorship W4306173665A5036625532 @default.
- W4306173665 hasAuthorship W4306173665A5041203253 @default.
- W4306173665 hasAuthorship W4306173665A5043177546 @default.
- W4306173665 hasAuthorship W4306173665A5048085062 @default.
- W4306173665 hasAuthorship W4306173665A5048352947 @default.
- W4306173665 hasAuthorship W4306173665A5053880366 @default.
- W4306173665 hasAuthorship W4306173665A5054413273 @default.
- W4306173665 hasAuthorship W4306173665A5054498659 @default.
- W4306173665 hasAuthorship W4306173665A5058504422 @default.
- W4306173665 hasAuthorship W4306173665A5059645677 @default.
- W4306173665 hasAuthorship W4306173665A5060569859 @default.
- W4306173665 hasAuthorship W4306173665A5068189051 @default.
- W4306173665 hasAuthorship W4306173665A5072578892 @default.
- W4306173665 hasAuthorship W4306173665A5073742272 @default.
- W4306173665 hasAuthorship W4306173665A5073894797 @default.
- W4306173665 hasAuthorship W4306173665A5077892396 @default.
- W4306173665 hasAuthorship W4306173665A5080788977 @default.
- W4306173665 hasAuthorship W4306173665A5081985776 @default.
- W4306173665 hasAuthorship W4306173665A5085058149 @default.